HER2-Targeted Therapy
Enhertu (trastuzumab deruxtecan) in Bahrain — Regulatory and Supply Information
HER2-directed antibody–drug conjugate (topoisomerase-I payload) for HER2-positive and HER2-low metastatic breast cancer after prior anti-HER2 therapy, HER2-mutant NSCLC, HER2-positive metastatic gastric cancer, and HER2-expressing solid tumors (pan-tumor accelerated approval). Standard dose 5.4 mg/kg every 3 weeks (breast); 6.4 mg/kg every 3 weeks (gastric).
Prescription-only medicine. No pricing is published on this page. Prescription-medicine pricing is not advertised to the public in this market.
This page is informational and is not an advertisement, a promotional communication, or medical advice. It does not offer any medicine for sale to the public. Treatment decisions belong to your treating physician.
What this medicine is
- Active ingredient
- trastuzumab deruxtecan
- Marketing authorisation holder
- Daiichi Sankyo / AstraZeneca
- Therapeutic class
- HER2-Targeted Therapy
Presentations and dosage forms
- 100 mg lyophilized powder vial (IV infusion, reconstitute + dilute)
Storage, cold chain and handling
Refrigerate 2–8°C, protect from light. After reconstitution use within 4 h at room temp or 24 h refrigerated.
The regulatory position in Bahrain
Medicines in the Kingdom of Bahrain are regulated by the National Health Regulatory Authority (NHRA).
We have not verified Bahrain's personal-import procedure from a primary source, so we do not describe one. Requirements should be confirmed directly with the NHRA before any step is taken.
What we can describe is the general concept that applies across the region: a named-patient supply. A named-patient supply is a quantity of a prescription medicine intended for one identified patient, requested by that patient's treating physician, documented by a prescription and a medical report, and handled through licensed channels with the cold chain and batch traceability intact. It is not a commercial sale to the public and it is not a substitute for a locally registered product where one is available.
Gathering the documentation below before contacting the authority usually shortens the process, whichever route the NHRA confirms applies.
We have not verified Bahrain's personal-import procedure. We do not describe one here. Confirm the current requirements with the NHRA.
Documentation typically required
- A valid prescription from the treating physician, naming the trade name, active ingredient, concentration and quantity
- A medical report describing the diagnosis and the treatment plan
- Proof of identity for the patient
- Confirmation from the treating clinician of the quantity required for the treatment course
- For a hospital or clinic: the establishment licence and the request of the responsible pharmacist
Official sources
Search terms for this medicine
The same molecule is searched under several names. All of the following refer to the same product:
- Enhertu
- trastuzumab deruxtecan
- إنهرتو
- تراستوزوماب ديروكستيكان
- Enhertu Bahrain
- إنهرتو البحرين
- trastuzumab deruxtecan NHRA
- Enhertu prescription
- إنهرتو وصفة طبية
Frequently asked questions
Prescription-based enquiry
If you hold a valid prescription from a treating physician in Bahrain, you can send us the prescription details and we will reply with the regulatory and documentation position for that specific product. We do not publish pricing for Bahrain and we do not sell to the public.
Send a prescription-based enquiryBackground reading
- Why medicines cost less in Türkiye
- How to verify a medicine is genuine
- WHO falsified medicine alerts
- Named patient supply
- For healthcare professionals
- Import guide — Bahrain
- Hospital & procurement — Bahrain
- Bahrain medicines
- Enhertu — Saudi Arabia
- Enhertu — Kuwait
- Enhertu — United Arab Emirates
- Enhertu — Qatar
- Enhertu — Azerbaijan
Related medicines
Medically reviewed by Pharmacy Remedy Pharmacovigilance & Compliance Desk · Last updated: 2026-07-29 · National Health Regulatory Authority
For healthcare professionals
Prescribers, hospital and specialty pharmacies, oncology centres and procurement departments: named patient supply, documentation and the sourcing workflow.